A GLP-1 injection pen, now just a few clicks away, raising questions about convenience, oversight and long-term care.

getty

You could stand to lose a few pounds. Fortuitously, an ad pops up on Instagram for direct-to-consumer GLP-1 medication. You click the link. A quick survey. A brief chat. A prescription, delivered. No appointments. No delays. No real conversation.

It feels like progress. Real access. A win.

But something crucial just got removed from the equation: your primary care physician. Convenience is replacing coordination. You are in control. However, you are making the decisions that used to be guided by someone who practices medicine. But it can be managed if you know where to look.

What’s being optimized here is speed, not a game plan. GLP-1 medication is just the tip of the iceberg, although it’s a huge tip. Direct-to-consumer medications also include sexual health medications like Viagra and Cialis, antidepressants (Lexapro, Zoloft, Prozac), sleep optimization drugs and hormone therapy. The DTC model is huge because it removes friction, making acquiring meds effortless. The only problem? Medicine needs friction. Without context or comprehensive evaluation, patients are making isolated decisions about complex systems on their own. Or with the help of Dr. Google (which receives an estimated 70,000 health-related searches a minute.)

This isn’t a niche trend. It’s a big swing. Healthcare is moving from something managed by your doctor to a consumer marketplace where you can get mental health medication without even a live conversation. The doctor in the Norman Rockwell painting would not have imagined this.

Direct-to-consumer platforms are addressing a real access problem, particularly for patients who are uninsured or underinsured. But that access often comes at a higher cost, especially for those who could otherwise go through insurance. Rather than replacing the traditional system, these platforms are emerging as an additional layer—expanding options, while also making the landscape more complex to navigate.

A STAT investigation found that a surprisingly small number of clinician networks are driving a large share of online GLP-1 prescribing, operating across dozens of websites and extending to compounded versions that are still being debated by clinicians and industry alike.

This isn’t just about GLP-1s. It’s about how medications are reaching patients in the first place. Direct-to-consumer platforms that are powered by telehealth, digital marketing, and cash-pay models are reshaping access to prescription drugs. Roughly 40 million Americans have used GLP-1s for weight loss alone. The market for direct-to-consumer weight-loss medications alone is projected to exceed $35 billion over the next decade, fueled by demand that is already mainstream. Nearly one in five U.S. adults has tried a GLP-1, and millions more are considering it.

Convenience is king. But leapfrogging your primary care physician can come with consequences. Your PCP is the only person responsible for seeing the full picture: your medical history, medications, lab trends and the patterns that don’t appear in an online intake. When you bypass that layer, prescriptions are made in isolation. That’s where things slip. Things like drug interactions, missed diagnoses or treatments that solve one problem while quietly creating another. Direct-to-consumer platforms are built for speed. Primary care is built for continuity. And in medicine, continuity is what keeps small decisions from turning into bigger problems. In addition, especially with GLP-1s, a team of providers is ideal to make sure patients reach their weight loss goals safely. This would include a nutritionist and a trainer to help monitor progress and prevent muscle loss.